INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Larimar Therapeutics, Inc. following a significant stock price drop after the release of clinical trial data [1] Group 1: Company Overview - Larimar Therapeutics, Inc. is publicly traded on NASDAQ under the ticker LRMR [1] - The company is currently conducting a long-term open-label study on Nomlabofusp for treating Friedreich's Ataxia [1] Group 2: Recent Developments - On September 29, 2025, Larimar announced "positive" data from its ongoing study, but also reported seven cases of anaphylaxis among participants [1] - Following the announcement, Larimar's stock price decreased by $1.72, representing a 33.66% decline, closing at $3.38 per share [1]